Martin A. Pule

London, ENG WC1E6DD, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 88 publications

CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis.

CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis.

Journal: Science translational medicine

Published: July 01, 2026

Antibody format matters: A comparative analysis of VHH and scFv domains reveals superior in vivo CAR T cell function with VHH domains.

Antibody format matters: A comparative analysis of VHH and scFv domains reveals superior in vivo CAR T cell function with VHH domains.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: December 04, 2025

Regulatory T cell depletion promotes myeloid cell activation and glioblastoma response to anti-PD1 and tumor-targeting antibodies.

Regulatory T cell depletion promotes myeloid cell activation and glioblastoma response to anti-PD1 and tumor-targeting antibodies.

Journal: Immunity

Published: May 30, 2025

Preclinical development of anti-CD21 chimeric antigen receptor T cells to treat T cell acute lymphoblastic leukemia.

Preclinical development of anti-CD21 chimeric antigen receptor T cells to treat T cell acute lymphoblastic leukemia.

Journal: Science translational medicine

Published: April 16, 2025

Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia.

Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia.

Journal: The New England journal of medicine

Published: November 27, 2024

Reply to: Oligoclonality of TRBC1 and TRBC2 in T cell lymphomas as mechanism of primary resistance to TRBC-directed CAR T cell therapies.

Reply to: Oligoclonality of TRBC1 and TRBC2 in T cell lymphomas as mechanism of primary resistance to TRBC-directed CAR T cell therapies.

Journal: Nature communications

Published: October 13, 2024

In Situ Tracking of TCRβ Isoforms for Detection of T Cell Clonality: Implication for Precision Diagnosis and Targeted Immunotherapy of T-Cell Neoplasms.

In Situ Tracking of TCRβ Isoforms for Detection of T Cell Clonality: Implication for Precision Diagnosis and Targeted Immunotherapy of T-Cell Neoplasms.

Journal: Hematological oncology

Published: September 22, 2024

Designer Small-Molecule Control System Based on Minocycline-Induced Disruption of Protein-Protein Interaction.

Designer Small-Molecule Control System Based on Minocycline-Induced Disruption of Protein-Protein Interaction.

Journal: ACS chemical biology

Published: January 20, 2024

TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial.

TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial.

Journal: Nature medicine

Published: January 18, 2024

Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR.

Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: December 16, 2023

Dual T-cell constant β chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry.

Dual T-cell constant β chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry.

Journal: Blood cancer journal

Published: December 01, 2023

Large-scale manufacturing of base-edited chimeric antigen receptor T cells.

Large-scale manufacturing of base-edited chimeric antigen receptor T cells.

Journal: Molecular therapy. Methods & clinical development

Published: August 15, 2023

Showing 1-12 of 88

Last Updated: 09/26/2026